Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):173-84.

Clinical applications of anticancer drugs targeted to topoisomerase II.

Author information

  • 1Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-5536, USA.

Abstract

Agents which 'poison' the enzyme topoisomerase II, have proven to be useful drugs for cancer treatment. Six antineoplastic drugs, which target topoisomerase II (doxorubicin, daunorubicin, idarubicin, mitoxantrone, etoposide and teniposide) are currently approved for clinical use in the United States. In this paper, the strategies and goals of cancer chemotherapy are summarized for the non-clinician. The use, pharmacology and toxicity of each of the six currently approved topoisomerase II inhibiting agents are reviewed.

PMID:
9748560
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk